{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005168334,0.0006461744,0.001616377,0.0002907482,0.0001919109,0.0007962127,0.000448409,0.0005428567,0.001878499],"category_scores_gemma":[0.003484441,0.0002836861,0.001665759,0.0003143798,0.0005285731,0.0005342758,0.0003487949,0.001123319,0.0002860402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005810795,"about_ca_system_score_gemma":0.0007965337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002236802,"about_ca_topic_score_gemma":0.0008000455,"domain_scores_codex":[0.9974691,0.001825541,0.000158681,0.0002625398,0.0001719053,0.0001123323],"domain_scores_gemma":[0.9977942,0.0006865645,0.0009740301,0.0001744612,0.0001046825,0.0002660867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9057417,0.002418202,0.03735014,0.0007319402,0.004919137,0.0000621913,0.00009991426,0.001129079,0.004089628,0.0001579815,0.001204912,0.04209528],"study_design_scores_gemma":[0.6918704,0.1459816,0.1434538,0.000151669,0.006765815,0.0004645396,0.0001022089,0.003649743,0.003550496,0.0006038673,0.003337473,0.00006837993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924266,0.004224028,0.000489399,0.0004529337,0.00005685427,0.0007055494,0.0006833494,0.00004470998,0.0009164712],"genre_scores_gemma":[0.9960935,0.0007705831,0.0005517292,0.0003616097,0.0001200148,0.0007539087,0.0009982339,0.000007282206,0.0003431477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005168334,"threshold_uncertainty_score":0.02733308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04313391345594417,"score_gpt":0.2807608521821021,"score_spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}